Mantle Cell Lymphoma

The overall mortality rate for patients with mantle cell lymphoma who contract COVID-19 is high, and mortality rates rise significantly in patients who are hospitalized or enter intensive care units, according to findings from a retrospective study that were published in Hemasphere.

The combination of bendamustine and rituximab plus autologous stem cell transplantation and maintenance rituximab was shown to be an effective first-line treatment with comparable outcomes to R-CHOP/R-DHAP plus ASCT and observation in young patients with transplant-eligible mantle cell lymphoma.

Martin Dietrich, MD, PhD, discusses optimizing treatment options for patients with mantle cell lymphoma.

Zanubrutinib monotherapy continues to demonstrate durable responses with an acceptable toxicity profile in patients with relapsed or refractory mantle cell lymphoma.

A Type II variation application seeking the approval of a new indication for ibrutinib plus bendamustine and rituximab in adult patients with previously untreated mantle cell lymphoma who are not candidates for autologous stem cell transplant has been submitted to the European Medicines Agency.

Martin Dietrich, MD, PhD, discusses the current treatment landscape of mantle cell lymphoma.

Treatment with the CD19-directed CAR T-cell therapy brexucabtagene autoleucel demonstrated significant activity, marked by high response rates and prolonged survival, in patients with relapsed mantle cell lymphoma in the pivotal ZUMA-2 trial.

Although the addition of copanlisib to ibrutinib resulted in a high overall response rate in patients with relapsed/refractory mantle cell lymphoma, the regimen was found to have additive toxicity, according to findings from a small phase 1 trial.

The combination of ibrutinib given at 420 mg and venetoclax at 200 mg elicited an objective response rate of 93.8% in patients with relapsed/refractory mantle cell lymphoma, according to results of a phase 1 dose-finding study.

Michael Wang, MD, discusses adverse effects associated with BTK inhibitors in patients with mantle cell lymphoma.

Michael Wang, MD, discusses potential adverse effects associated with ibrutinib in patients with mantle cell lymphoma.

Michael Wang, MD, discusses the sequencing of oral therapies in mantle cell lymphoma.

Michael Wang, MD, discusses the evolution of ibrutinib in the treatment landscape of mantle cell lymphoma.

The combination of ibrutinib plus rituximab generated a high rate of complete response and undetectable minimal residual disease when used in the frontline treatment of patients with indolent clinical forms of mantle cell lymphoma, allowing for treatment interruption in most responders.

Induction treatment with ibrutinib and rituximab was safe and active in patients with mantle cell lymphoma aged 65 years or younger, allowing for fewer cycles of subsequent chemotherapy with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone thereby reducing toxicity.

Michael Wang, MD, discusses the evolving treatment landscape of mantle cell lymphoma.

Despite the breakthroughs in the development of therapeutic regimens for patients with mantle cell lymphoma, variability in treatment pathways presents a unique hurdle in determining the appropriate course of care following disease progression.

Tycel Jovelle Phillips, MD, discusses the current role of ibrutinib in mantle cell lymphoma.

The global biopharmaceutical company Incyte has decided to withdraw the new drug application for parsaclisib for the treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma.

A brief review of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma as studied in the ZUMA-2 clinical trial of brexucabtagene autoleucel.

Moving to second-line therapy for mantle cell lymphoma, experts discuss available BTK inhibitors, including the novel agent pirtobrutinib.

Dr Wang discusses the clinical experience with ibrutinib in mantle cell lymphoma, its present role in the management of MCL, and ongoing research that may affect its use as a single agent.

Tycel Jovelle Phillips, MD, discusses ongoing research with BTK inhibitors in mantle cell lymphoma.

Matthew S. McKinney, MD, discusses the potential for curative-intent therapies in mantle cell lymphoma.

The combination of ibrutinib and rituximab produced a high overall response rate and durable survival in elderly patients with mantle cell lymphoma.